

# **Evaluation of the Prophylactic Antibiotic Policies of Cardiac Surgery in a University Teaching Hospital**

A Thesis for the Fulfillment of the Master Degree in Pharmaceutical Sciences  
(Clinical Pharmacy)

Submitted to Faculty of Pharmacy, Ain Shams University

*By the Pharmacist*

**Shaymaa Mohammad Mohammad Youssef El-Awady**

B.sc. of pharmaceutical science (2001)  
Faculty of pharmacy, Ain Shams University

*Under Supervision of*

**Prof. Dr. Manal Hamed El-Hamamsy**

Professor of Clinical Pharmacy  
Faculty of Pharmacy  
Ain Shams University

**Prof. Dr. Ahmed Samy Taha**

Professor of Cardiac and Thoracic Surgery  
Faculty of Medicine  
Ain Shams University

**Dr. Basemah Fawzy Mohammed Awad**

Fellow Intensive Care and Echocardiography  
Faculty of Medicine  
Ain Shams University

Faculty of Pharmacy  
Ain Shams University  
**2015**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

يشاء  
هذا  
نسيت  
يهدين  
" ٢٣  
٢٤  
[الكهف: ٢٣ ، ٢٤]

صدق الله العظيم

## ***Acknowledgement***

*First and above all, I praise God, the almighty for providing me this opportunity and granting me the capability to proceed successfully. This thesis appears in its current form due to the assistance and guidance of several people. I would therefore like to offer my sincere thanks to all of them.*

*Prof. Dr Manal Hamed El-Hamamsy, your warm encouragement, trust, thoughtful guidance, and your support during the whole period of the study.*

*I want to express my deep thanks to Dr Basemah Mohammed Fawzy Awad for the insightful discussion, offering valuable advice, and especially for your patience and guidance during the writing process.*

*Also, I would like to thank my supervisor Dr Ahmed Samy Taha for his efforts and time.*

*Radwa Ahmed and Reham Kamel, I greatly appreciate your assistance and your spiritual supports for me during my master study.*

*Thanks also to all the patients and the members of the cardiac surgery department in Ain Shams University Hospitals, for their support and cooperation.*

*Finally, and most importantly, I would like to thank my parents for their faith in me and allowing me to be as ambitious as I wanted. It was under their watchful eye that I gained so much drive and an ability to tackle challenges head on. I would like to thank my husband Ahmed Helal. His support, encouragement and quiet patience were undeniably.*

## *List of Contents*

<i>Contents</i>	<i>Page Number</i>
<b>List of Abbreviations.....</b>	<b>I</b>
<b>List of Figures.....</b>	<b>II</b>
<b>List of Tables.....</b>	<b>IV</b>
<b>Abstract.....</b>	<b>V</b>
<b>Review of Literature</b>	
<b>Heart Diseases and Their Surgical Management.....</b>	<b>1</b>
<b>The Immune System.....</b>	<b>11</b>
<b>Cardiopulmonary Bypass.....</b>	<b>20</b>
<b>Postoperative Period in Cardiac Surgery Intensive Care Unit.....</b>	<b>24</b>
<b>Nosocomial Infection and its Preventive Measures.....</b>	<b>27</b>
<b>Antibiotic Prophylaxis.....</b>	<b>42</b>
<b>Pharmaceutical Care in The Intensive Care Unit.....</b>	<b>53</b>
<b>Economic Aspects of Antibiotic Resistance.....</b>	<b>55</b>
<b>Aim of the Work.....</b>	<b>57</b>
<b>Patients And Methods.....</b>	<b>58</b>
<b>Results.....</b>	<b>70</b>
<b>Discussion.....</b>	<b>98</b>
<b>Summary.....</b>	<b>107</b>
<b>Conclusion, Limitations and Recommendations.....</b>	<b>111</b>
<b>References.....</b>	<b>113</b>
<b>Arabic Summary.....</b>	<b>0-1</b>

---

## *List of Abbreviations*

<b>ABD</b>	Acid base difficile
<b>ALT</b>	Alanine transaminase
<b>ANOVA</b>	Analysis of variance
<b>AR</b>	Aortic Regurgitation
<b>AS</b>	Aortic Stenosis
<b>ASD</b>	Arterial septal defect
<b>AST</b>	Aspartate aminotransferase
<b>BSI</b>	Blood stream infection
<b>CABG</b>	Coronary Artery Bypass Graft
<b>CoA</b>	Coarctation of aorta
<b>ICU</b>	Intensive care unit
<b>MANOVA</b>	Multivariate Analysis of variance
<b>MR</b>	Mitral Regurgitation
<b>MRSA</b>	<i>Methicillin-resistant Staphylococcus aureus</i>
<b>MS</b>	Mitral Stenosis
<b>NS</b>	Not significant
<b>PCO<sub>2</sub></b>	Partial pressure of carbon dioxide
<b>PDA</b>	Patent ductus arteriosus
<b>PO<sub>2</sub></b>	Partial pressure of oxygen
<b>q</b>	Every
<b>SSI</b>	Surgical site infection
<b>STS</b>	Society of thoracic Surgeons
<b>TOF</b>	Tetralogy of Fallot
<b>VSD</b>	Ventricular septal defect

## *List of Figures*

<i><b>Figure Number</b></i>	<i><b>Figure Title</b></i>	<i><b>Page Number</b></i>
<b>Figure (1)</b>	Diagram demonstrating the cardiopulmonary bypass machine	<b>20</b>
<b>Figure (2)</b>	Sites of antibacterial action	<b>42</b>
<b>Figure (3)</b>	Demographic data among the pediatrics groups	<b>71</b>
<b>Figure (4)</b>	Demographic data among the adults groups	<b>71</b>
<b>Figure (5)</b>	Types of cardiac surgeries of group IA (pediatric patients with postoperative infection) and group IIA (pediatric patients without postoperative infection)	<b>73</b>
<b>Figure (6)</b>	Types of cardiac surgeries of group IB (adult patients with postoperative infection) and group IIB (adult patients without postoperative infection)	<b>73</b>
<b>Figure (7)</b>	Postoperative laboratory finding among the pediatrics groups	<b>77</b>
<b>Figure (8)</b>	Postoperative laboratory finding among the adults groups	<b>77</b>
<b>Figure (9)</b>	Duration of exposure to infection, durations of stay, antibiotic use and protocol duration in Group IA (pediatric patients with postoperative infection) and Group IIA (pediatric patients without postoperative infection)	<b>79</b>
<b>Figure (10)</b>	Duration of exposure to infection, durations of stay, antibiotic use and protocol duration in Group IB (adult patients with postoperative infection) and Group IIB (adult patients without postoperative infection)	<b>79</b>
<b>Figure (11)</b>	Mortality among pediatric groups with respect to infection	<b>83</b>
<b>Figure (12)</b>	Mortality among adult groups with respect to infection	<b>83</b>
<b>Figure (13)</b>	Relative percentage of the type of infection shown in group IA (pediatric patients with postoperative infection)	<b>84</b>
<b>Figure (14)</b>	Relative percentage of the type of infection shown in group IB (adult patients with postoperative infection)	<b>84</b>

---

<i><b>Figure Number</b></i>	<i><b>Figure Title</b></i>	<i><b>Page Number</b></i>
<b>Figure ( 15)</b>	Anti-infectious agents used by group I A (pediatric patients with postoperative infection) (N=44)	<b>89</b>
<b>Figure ( 16)</b>	Secondary protocols for resistant patients regarding the applied routine protocols for group IA: pediatric patients (N=44)	<b>89</b>
<b>Figure (17 )</b>	Anti-infectious agents used by group IB (adult patients with postoperative infection) (N=59)	<b>89</b>
<b>Figure (18)</b>	Secondary protocols for resistant patients regarding the applied routine protocols for group IB: adult patients	<b>89</b>
<b>Figure (19)</b>	Antibiotic types and total antibiotic doses used among pediatrics groups	<b>91</b>
<b>Figure (20)</b>	Antibiotic types and total antibiotic doses used among adults groups	<b>91</b>
<b>Figure (21)</b>	The percentage of the number of antibiotic types used for group IA (pediatric patients with postoperative infection) and group IIA (pediatric patients without postoperative infection)	<b>92</b>
<b>Figure (22)</b>	The percentage of the number of antibiotic types used for group IB (adult patients with postoperative infection) and Group IIB (adult patients without postoperative infection)	<b>92</b>
<b>Figure (23)</b>	The percentage of the total antibiotic doses used for group IA (pediatric patients with postoperative infection) and group IIA (pediatric patients without postoperative infection)	<b>92</b>
<b>Figure (24)</b>	The percentage of the total antibiotic doses used for group IB (adult patients with postoperative infection) and group IIB (adult patients without postoperative infection)	<b>92</b>
<b>Figure (25)</b>	Microorganisms isolated in Group IA (pediatric patients with postoperative infection)	<b>95</b>
<b>Figure (26)</b>	Microorganisms isolated in Group IA (pediatric patients with postoperative infection)	<b>95</b>

---

## *List of Tables*

<b><i>Table Number</i></b>	<b><i>Table Title</i></b>	<b><i>Page Number</i></b>
<b>Table (1)</b>	Classification of patients selected in the study	<b>58</b>
<b>Table (2)</b>	The three protocols regimens used for postoperative prophylactic antibiotics	<b>62</b>
<b>Table (3)</b>	Secondary protocols for resistant infected patients	<b>63</b>
<b>Table (4)</b>	All the antibiotic and antifungal drugs used by the 320 patients in the ICU and the ward at the hospital	<b>64</b>
<b>Table (5)</b>	Criteria to assess adherence and compliance with current antimicrobial prophylaxis practices within in the unit of cardiac surgery department in Ain Shams University Hospitals	<b>68</b>
<b>Table (6)</b>	Demographic data of the study patients (N=320)	<b>70</b>
<b>Table (7)</b>	Comparison of demographic characteristics between Group I and Group II	<b>71</b>
<b>Table (8)</b>	Postoperative signs of infection for the study patients (N=320)	<b>72</b>
<b>Table (9)</b>	types of cardiac surgery of the study patients (N=320)	<b>75</b>
<b>Table (10)</b>	Comparison of laboratory findings between Group I and Group II	<b>76</b>
<b>Table (11)</b>	Duration of exposure to infection among pediatric and adult groups with respect to infection	<b>78</b>
<b>Table (12)</b>	Adherence to International Guidelines in Antimicrobial Prophylaxis in Cardiac Surgery	<b>80</b>
<b>Table (13)</b>	Postoperative complications among the study Groups (N=320)	<b>82</b>
<b>Table (14)</b>	Infection types of Group I (patients with postoperative infection) (N=103)	<b>84</b>
<b>Table (15)</b>	Anti-infectious agents and number of antibiotics used by Group I (patients with postoperative infection) (N=103):	<b>86</b>
<b>Table (16)</b>	Secondary Protocols for resistant patients regarding the applied routine protocols for Group I (patients with postoperative infection) (N=103)	<b>88</b>
<b>Table (17)</b>	Anti-infectious agents and number of antibiotics used by Group II (patients without postoperative infection) (N=217)	<b>91</b>
<b>Table (18)</b>	Microorganisms isolated in Group I (patients with postoperative infection) (N=103)	<b>94</b>
<b>Table (19)</b>	Microorganisms isolated regarding the applied routine protocols for Group I (Patients with postoperative infection) (N=103)	<b>97</b>

---

# *Abstract*

---

## **Abstract**

**Background:** Antimicrobial prophylaxis in cardiac surgery has been demonstrated to lower the incidence of postoperative infection. Inappropriate antimicrobial prophylaxis, as inappropriate selection of the antimicrobial agent or dosing regimen, can increase the prevalence of antibiotic resistant strains, prolong hospital stay, cause postoperative infection, and negatively affect an institution's pharmacy budget for antibiotics.

**Objective:** To assess the current postoperative prophylactic antibiotic protocols applied in the cardiac surgeries department in Ain Shams University teaching hospitals with respect to others and to international guidelines for antimicrobial prophylaxis practice in cardiac surgery.

**Methods:** 320 pediatric and adult patients who were admitted for cardiac surgery to Ain Shams University teaching hospitals from September 2012 until March 2013. The antimicrobial prophylaxis indication, choice, duration, dose, dosing interval, and timing appropriateness were assessed against 3 international guidelines using a pre-tested, structured clinical data collection form. The study design was prospective observational. All study patients were monitored daily during their inpatient stay until discharge. Data regarding surgery duration, mechanical ventilation duration, intensive care unit stay, postoperative stay and total hospital stay were obtained.

**Results:** Adherence to all antimicrobial prophylaxis guidelines was not achieved for any study patients. A statistical significant difference for the mechanical ventilation duration, Intensive care unit stay, postoperative stay and total hospital stay were found concerning both the pediatrics and the adults between the infected and non-infected group.

**Conclusion:** Study findings indicate that adherence to international guidelines for antimicrobial prophylaxis is far from optimal in cardiothoracic department at Ain Shams University teaching hospitals, due to the inappropriate administration of many antibiotics. Developing local hospital guidelines, as well as giving the clinical pharmacist a central role in the administration, monitoring, and intervention of antimicrobial prophylaxis may improve the current practice.

**Key Words:** Prophylactic Antibiotic, Antibiotic Resistance, Nosocomial Infection, Clinical Pharmacy.

---

# *Review of Literature*

---

## **Common Heart Diseases and their Surgical Management**

Over the past century, cardiac surgery has undergone remarkable development and growth, most notably within the past 50 years, with the evolution of cardiopulmonary bypass capabilities (**Daly *et al.*, 2005**).

Cardiopulmonary bypass was introduced in the 1950s to provide a bloodless field and quickly became the gold standard of providing extracorporeal circulation. In 1954, perfusion of oxygenated blood during a cardiac procedure through controlled cross circulation was supported. In 1954 a “mechanical heart lung machine” was used to shunt blood around the heart and lungs and provide direct visualization and a bloodless field for cardiac procedures (**Gibbon *et al.*, 1954**).

Heart diseases are classified into adult heart diseases and pediatric heart diseases (**Bonow *et al.*, 2006**).

### **Adult Heart Diseases**

Cardiovascular disease can take many forms: coronary artery disease, valvular heart disease or rheumatic fever / rheumatic heart disease (**Veinot *et al.*, 2006**).

#### **1) Valvular Heart Diseases**

##### **Rheumatic heart disease**

Before antibiotic medicines became widely used, rheumatic fever was the biggest cause of valve disease. Rheumatic fever is a complication of untreated streptococcal throat, which is caused by a group A -hemolytic streptococcal infection of the respiratory tract in addition to other environmental and genetic factors. It leads to scarring of the heart's valves leading to narrowing of the valve and make it harder for the valve to open properly or to close completely (**Steer *et al.*, 2009**).

##### **1. Mitral Valve Disease**

###### **i. Mitral Stenosis (MS)**

It refers to narrowing of the mitral valve orifice. It is usually caused by rheumatic heart disease. Less common causes include infective endocarditis and systemic lupus erythematosus (**Bonow *et al.*, 2008**).

**Surgical Management:** It consists of mitral valvotomy (which can be either surgical or percutaneous) or mitral valve replacement. The surgical mitral valvotomy approach can be through a closed or open technique; the latter technique is rarely used, except in developing countries, and has largely been replaced by the percutaneous balloon commissurotomy (**Rahimtoola, 2010**).

Surgical valve repair may involve opening a narrowed valve by removing calcium deposits or reinforcing a valve that does not close properly. Moreover, with percutaneous balloon valvuloplasty / percutaneous mitral commissurotomy (PMC), a catheter is directed into the left atrium after transseptal puncture, and a balloon is directed across the valve and inflated in the orifice. This results in separation of the mitral leaflets (**Holmes et al., 2011**).

With Surgical valvotomy/valve replacement, a defective valve is removed and a prosthetic valve is stitched in its place (**Vahanian et al., 2012**).

***There are two kinds of prosthetic valves used for valve replacement:***

- **Mechanical valves:** - usually made from materials such as plastic, carbon, or metal. Mechanical valves are strong, and they last a long time. Because blood tends to stick to mechanical valves and create blood clots, patients with these valves need to take blood-thinning medicines (called anticoagulants) for the rest of their lives (**Rahimtoola et al., 2010**).

- **Biological valves :-**

**Xenograft** → which are made from animal tissue like pig.

**Allograft or homograft** → taken from the human tissue of a donated heart.

**Autograft** → a patient's own tissue used for valve replacement.

Patients with biological valves usually do not need to take blood-thinning medicines. These valves are not as strong as mechanical valves and they may need to be replaced every 10 years (**Stassano et al., 2009**).

## **ii. Mitral Regurgitation (MR)**

It is leakage of blood from the left ventricle into the left atrium during systole. It is caused by structural or functional abnormalities of the mitral apparatus, adjacent myocardium, or both. The most common causes of mitral regurgitation are rheumatic heart disease, infective endocarditis, coronary artery disease, and cardiomyopathy (**Barbieri et al., 2011**).

### **Surgical Management:**

- Valve Repair through Valvuloplasty, which strengthens the leaflets to provide more support and to let the valve close tightly. This support comes from a ring-like device that surgeons attach around the outside of the valve opening.
- Also Valve Repair of structural support, which replaces or shortens the cords that give the valves support (these cords are called the chordae tendineae and the papillary muscles). When the cords are the right length, the valve can close properly.
- Valve replacement (Clavel *et al.*, 2010).

### **iii. MITRAL VALVE PROLAPSE**

It is the most common valvular abnormality, it usually has a benign course, but it occasionally leads to serious complications, including clinically significant mitral regurgitation, infective endocarditis, sudden cardiac death, and cerebrovascular ischemic events and it is managed through mitral valve repair or mitral valve replacement (Izumo *et al.*, 2013).

## **2. Aortic Valve Disease**

### **i. Aortic Stenosis (AS)**

It refers to obstruction of flow at the level of the aortic valve leads to restricted systolic opening of the valve leaflets. Rheumatic and congenital aortic stenosis account for the majority of cases. Valvular aortic stenosis results in chronic left ventricular pressure overloading. It is managed through percutaneous balloon valvuloplasty, which is used as a palliative measure or Aortic valve replacement (Roberts *et al.*, 2012).

### **ii. Aortic Regurgitation (AR)**

It is defined by incompetence of the aortic valve, in which a portion of the left ventricular forward stroke volume returns to the chamber during diastole. It can occur because of leaflet pathology or aortic root disease and it is usually managed through aortic valve replacement (Roberts *et al.*, 2012).

## **3. Pulmonary Valve Stenosis**

It is usually present at birth where the pulmonary valve or the pulmonary artery just below the valve is narrowed. It is most commonly caused by a defect

during fetal development and it is managed through percutaneous balloon valvuloplasty or surgical valvotomy (**Odenwald *et al.*, 2011**).

It refers to abnormal function of the tricuspid valve and it includes two types:-

- i. **Tricuspid regurgitation:** - the valve is leaky or doesn't close tight enough, causing blood to leak backwards across the valve.
- ii. **Tricuspid stenosis:** - the valve leaflets are stiff and do not open widely enough, causing a restriction in the forward flow of blood (**Roberts *et al.*, 2005**).

Tricuspid diseases are caused by rheumatic fever, infection, a dilated right ventricle and pulmonary hypertension and it is managed through valve repair or valve replacement (**Sharieff *et al.*, 2005**).

## **2) Coronary Artery Disease (Ischemic Heart Disease)**

It is the narrowing or blockage of the coronary arteries, usually caused by atherosclerosis. The major risk factors are smoking, diabetes mellitus and Hypercholesterolemia together with the hypertension, Genetic and hereditary factors and stress (**Stone *et al.*, 2013**).

Atherosclerosis (hardening or clogging) of the arteries is the buildup of cholesterol and fatty deposits (called plaques) on the inner walls of the arteries which restrict blood flow to the heart muscle by physically clogging the artery or by causing abnormal artery tone and function (**Park *et al.*, 2009**).

Ischemia is a condition described as “cramping of the heart muscle “and it occurs when the narrowed coronary artery reaches a point where it cannot supply enough oxygen-rich blood to meet the heart’s needs. Without an adequate blood supply, the heart becomes starved of oxygen and the vital nutrients it needs to work properly. This can cause chest pain called angina which is the most common symptom of coronary artery disease that is manifested by a chest pain (**Mosca *et al.*, 2011**).

A collateral circulation is the development of new blood vessels that reroute blood flow around the blockage. If blood supply to a portion of the heart muscle is cut off entirely, or if the energy demands of the heart become much greater than its blood supply, a heart attack may occur (**Greenland *et al.*, 2010**).